Publications

Empiric tuberculosis treatment in South African primary health care facilities - for whom, where, when and why: Implications for the development of tuberculosis diagnostic tests.

McCarthy, K; FIELDING, K; CHURCHYARD, GJ; GRANT, AD;

2018

PloS one, (2018).13 1 10.1371/journal.pone.0191608.

The utility of repeat Xpert MTB/RIF testing to diagnose tuberculosis in HIV-positive adults with initial negative result.

Hanifa, Y; FIELDING, KL; Chihota, VN; Adonis, L; Charalambous, S; FOSTER, N; Karstaedt, A; McCarthy, K; Nicol, MP; Ndlovu, NT; Sinanovic, E; Sahid, F; Stevens, W; VASSALL, A; Churchyard, GJ; GRANT, AD;

2018

Gates open research, (2018).2, 10.12688/gatesopenres.12815.1.

Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid.

Requena-Méndez, A; Davies, G; Waterhouse, D; Ardrey, A; Jave, O; López-Romero, SL; Ward, SA; MOORE, DA J;

2018

The Journal of antimicrobial chemotherapy, (2018).74 2 10.1093/jac/dky444.

The adolescent tuberculosis care cascade: an urgent need to address high rates of loss to follow-up from diagnosis to cure.

KHAN, PY;

2018

Public health action, (2018).8 3 10.5588/pha.18.0059.

Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis.

COLL, F; PHELAN, J; Hill-Cawthorne, GA; Nair, MB; Mallard, K; Ali, S; Abdallah, AM; Alghamdi, S; Alsomali, M; Ahmed, AO; Portelli, S; OPPONG, Y; Alves, A; Bessa, TB; CAMPINO, S; Caws, M; Chatterjee, A; CRAMPIN, AC; DHEDA, K; FURNHAM, N; GLYNN, JR; Grandjean, L; Minh Ha, D; Hasan, R; Hasan, Z; ... CLARK, TG.

2018

Nature genetics, (2018).50 2 10.1038/s41588-017-0029-0.

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.

FLETCHER, HA; Chatterjee, M; Cooper, A; Hussell, T; Kaye, PM; Prior, J; Reljic, R; Vermaak, S; Vordermeier, M; Williams, A; McShane, H;

2018

F1000Research, (2018).7, 10.12688/f1000research.14386.1.

Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.

Obregón, G; Zevallos, K; Alarcón, V; Puyén, ZM; Chávez Inagaki, O; Mendoza-Ticona, A; Alarcón-Arrascue, E; Heldal, E; MOORE, DA J;

2018

The international journal of tuberculosis and lung disease, (2018).22 11 10.5588/ijtld.17.0894.

Risk of Mycobacterium tuberculosis transmission in an antiretroviral therapy clinic.

MZEMBE, T; MCLEAN, E; KHAN, PY; KOOLE, O; Sichali, L; Mwinuka, V; Kayange, M; Mzumara, P; Dimba, A; CRAMPIN, AC; GLYNN, JR;

2018

AIDS (London, England), (2018).32 16 10.1097/QAD.0000000000002006.

Tuberculosis vaccines: Opportunities and challenges.

Zhu, B; DOCKRELL, HM; Ottenhoff, TH M; Evans, TG; Zhang, Y;

2018

Respirology (Carlton, Vic), (2018).23 4 10.1111/resp.13245.

Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.

Bock, P; Fatti, G; Ford, N; Jennings, K; Kruger, J; Gunst, C; Louis, F; Grobbelaar, N; Shanaube, K; FLOYD, S; Grimwood, A; HAYES, R; AYLES, H; Fidler, S; Beyers, N; HPTN 071 (PopART) trial team,;

2018

PloS one, (2018).13 4 10.1371/journal.pone.0195127.